ARTICLE CONCERNING HEART DISEASE
U.S. Orders Resistance Warnings on Antibiotics
By Lisa Richwine
WASHINGTON (Reuters) - Antibiotics will need to carry warnings advising doctors to avoid unnecessary prescriptions, a major contributor to the problem of drug-resistant infections, U.S. health officials said on Wednesday.
The new requirement aims to reduce inappropriate prescribing of antibiotics for common ailments such as ear infections and chronic coughs, which often are caused by viruses that do not respond to antibiotics.
Antibiotics only kill bacteria, but patients often request them for treating a variety of infections.
Starting next year, antibiotic labels should include instructions for doctors to prescribe them only when an infection is proven or strongly suspected to be caused by bacteria, the Food and Drug Administration (news - web sites) said.
The labels also will encourage physicians to counsel patients about what types of infections require antibiotic treatment, as well as remind them to take all of their medication, even if they feel better in a few days.
Not completing a full course of treatment can give microbes the chance to mutate to resist antibiotics, causing infections that are harder to treat. Overprescribing the drugs also is considered a major reason that antibiotic resistance is increasing.
According to the Centers for Disease Control and Prevention (news - web sites), half of the 100 million prescriptions a year written by office-based physicians in the United States are unnecessary because they are prescribed for the common cold and other viral infections.
"Antibiotic resistance is a serious and growing public health problem, not only in this country but worldwide," FDA Commissioner Mark McClellan said, noting that the growth of resistant germs is outpacing development of new antibiotics.
"We may end up in a situation where we don't have effective antibiotic drugs for common infections that were once easily treated," McClellan said in an interview.
The agency plans to try and publicize the warnings through medical journals and professional medical societies, McClellan said.
Jeff Trewhitt, a spokesman for the Pharmaceutical Research and Manufacturers of America, said the drug industry group had just begun reviewing the rule. He declined to comment further.
No comments:
Post a Comment
We do appreciate your feedback. We do ask that you do not spam or you will be blocked from future posting. Thanks.